De-risk and accelerate the drug development process for gene therapy

Cell & Gene Therapy Insights 2022; 8(8), 1141

DOI: 10.18609/cgti.2022.170

Published: 29 September 2022
Kim Watanabe

In today’s challenging financial environment, it is more important than ever to get key biotech business decisions right first time. One of the most important and topical of these is the choice of CDMO partner. Here, Dr. Kim Watanabe, General Manager and Site Head for Patheon Translational Services, a part of the Thermo Fisher Scientific pharma services contract development and manufacturing organizational arm, shares her advice and insights into optimizing outsourcing strategy.

You can view or download the poster here.

If you are interested in learning more, you can listen to the podcast here or read the full transcript here

Authorship & conflict of interest

Contributions: All named authors take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Acknowledgements: None.

Disclosure and potential conflicts of interest: The author has no conflicts of interest. 

Funding declaration: The author received no financial support for the research, authorship and/or publication of this article. 

Article & copyright information 

Copyright: Published by Cell and Gene Therapy Insights under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Attribution: Copyright © 2022 ThermoFisher Scientific. Published by Cell and Gene Therapy Insights under Creative Commons License Deed CC BY NC ND 4.0.

Article source: This article is based on a Podcast which took place on Aug 18 2022.

Podcast conducted on: Aug 18 2022; Revised manuscript received: Sep 23 2022; Publication date: Oct 3 2022.